Indolin-2-ones with high in vivo efficacy in a model for multiple sclerosis

Journal of Medicinal Chemistry

Volumn 48, Issue 17, 2005, Pages 5412-5414

  Bouérat, Laëtitia ^a,b   Fensholdt, Jef ^a   Liang, Xifu ^a   Havez, Sophie ^a   Nielsen, Simon F ^a   Hansen, Jens R ^a   Bolvig, Simon ^a   Andersson, Christina ^a,b  

^a LEO PHARMA A S   (Denmark)

^b Dept of Marketing Healthcare ^*

Author keywords

[No Author keywords available]

Indexed keywords

INDOLE DERIVATIVE; INTERLEUKIN 2; SEMAXANIB; SU 6595; SU 6689; SU 9838; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; VATALANIB;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL MODEL; ARTICLE; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN;

ANIMALS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; INDOLES; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; MICE; MULTIPLE SCLEROSIS; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 23944504717     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0504151     Document Type: Article

References (22)

1. Compston, A.; Coles, A. Multiple sclerosis. The Lancet 2002, 359, 1221-1231.
2. Noseworthy, J. H.; Luncinetti, C.; Rodriguez, M.; Weinschenker, B. G. Multiple sclerosis. N. Engl. J. Med. 2000, 343, 938-952.
3. Waubant, E. Emerging disease modifying therapies for multiple sclerosis. Expert Opin. Emerg. Drugs 2003, 8, 145-161.
4. Filippini, G.; Munari, L.; Incorvaia, B.; Ebers, G. C.; Polman, C.; D'Amico, R.; Rice, G. P. A. Interferons in relapsing remitting multiple sclerosis: a systematic rewiew. The Lancet 2003, 361, 545-552.
5. Fazekas, F.; Deisenhammer, F.; Strasser-Fuches, S.; Nahler, G.; Mamoli, B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian immunoglobulin in multiple sclerosis study group. The Lancet 1997, 349, 589-593.
6. Gonsette, R. E. A comparison of the benefits of mitroxantrone and other recent therapeutic approaches in multiple sclerosis. Expert Opin. Pharmacother. 2004, 5, 747-765.
7. Lublin, F. D.; Reingold, S. C. Defining the clinical course of multiple sclerosis: results of an international survey. National multiple sclerosis society (USA) advisory committee on clinical trials of new agents in multiple sclerosis. Neurology 1996, 46, 907-911.
8. Thompson, A. J.; Montalban, X.; Barkof, F.; Brochet, B.; Filippi, M.; Miller, D. H.; Polman C. H.; Stevenson, V. L.; McDonald, W. I. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann. Neurol. 2000, 47, 831-835.
9. Confavreux, C.; Vukusic, S.; Moreau, T.; Adeleine, P. Relapses and progression of disability in multiple sclerosis. N. Engl. J. Med. 2000, 343, 1430-1438.
10. Hemmer, B.; Archelos J. J.; Hartung, H. P. New concepts in the immunopathogenesis of multiple sclerosis. Nat. Rev. Neurosci. 2002, 3, 291-301.
11. Hart, B. A.; Amor, S. The use of animal models to investigate the pathogenesis of neuroinflammatory disorders of the central nervous system. Curr. Opin. Neurol. 2003, 16, 375-383.
12. Langecker, P. J.; Shawver, L. K.; Tang, P. C.; Sun, L. 3-Heteroarylidenyl-2-indolinone compound for modulating protein kinase activity and for use in cancer chemotherapy. WO patent 38519, 2000.
13. Smith, K. M.; Langry, K. C.; Minnetian, O. M. Peripheral mercuration of metalloporphyrins: novel syntheses of deoxophylloerythroetioporphyrin and deoxophylloerythrin methyl ester. J. Org. Chem. 1984, 49, 4602-4609.
14. Kende, A. S.; Thurston, J. Synthesis of 1-hydroxyoxindoles. Synth. Commun. 1990, 20, 2133-2138.
15. Antonian, L.; Zhang, H.; Yang, C.; Wagner, G.; Shawver, L. K.; Shet, M.; Ogilvie, B.; Madan, A.; Parkinson, A. Biotransformation of the anti-angiogenic compound SU5416. Drug Metab. Dispos. 2000, 28, 1505-1512.
16. Synthesized as described in ref 12.
17. Kirk, S.; Frank, J. A.; Karlik, S. Angiogenesis in multiple sclerosis: is it good, bad or an epiphenomenon? J. Neurol. Sci. 2004, 217, 125-130.
18. Bold, G.; Altmann, K.-H.; Frei J.; Lang, M.; Manley, P. W.; Traxler, P.; Wietfeld, B.; Brüggen, J.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Furet, P.; Hofmann, F.; Martiny-Baron, G.; Mestan, J.; Rösel, J.; Sills, M.; Stover, D.; Acernoglu, F.; Boss, E.; Emmenegger, R.; Lässer, L.; Masso, E.; Roth, R.; Schlachter, C.; Vetterli, W.; Wyss, D.; Wood, J. M. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor- driven angiogenesis. J. Med. Chem. 2000, 43, 2310-2323.
19. Neuhaus, O.; Archelos, J. J.; Hartung, H. Immunomudulation in multiple sclerosis: from immunosupression to neuroprotection. Trends Pharmacol. Sci. 2003, 24, 131-138.
20. Bundgaard, H. Design of Prodrugs; Elsevier: Amsterdam, 1985.
21. Ettmayer, P.; Amidon, G. L.; Clement, B.; Testa, B. Lessons learned from marketed and investigational prodrugs. J. Med. Chem. 2004, 47, 2393-2404.
22. Moon, M. W.; Morozowich, W.; Gao, P.; Tang, P. C. Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives. WO patent 90068A2, 2001.